265 related articles for article (PubMed ID: 11078217)
1. The developmental and aging changes of Down's syndrome cell adhesion molecule expression in normal and Down's syndrome brains.
Saito Y; Oka A; Mizuguchi M; Motonaga K; Mori Y; Becker LE; Arima K; Miyauchi J; Takashima S
Acta Neuropathol; 2000 Dec; 100(6):654-64. PubMed ID: 11078217
[TBL] [Abstract][Full Text] [Related]
2. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome.
Teller JK; Russo C; DeBusk LM; Angelini G; Zaccheo D; Dagna-Bricarelli F; Scartezzini P; Bertolini S; Mann DM; Tabaton M; Gambetti P
Nat Med; 1996 Jan; 2(1):93-5. PubMed ID: 8564851
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of E2F-1 in Down's syndrome brain exhibiting neuropathological features of Alzheimer-type dementia.
Motonaga K; Itoh M; Hirayama A; Hirano S; Becker LE; Goto Y; Takashima S
Brain Res; 2001 Jun; 905(1-2):250-3. PubMed ID: 11423103
[TBL] [Abstract][Full Text] [Related]
4. NMDA-mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome.
Alves-Sampaio A; Troca-Marín JA; Montesinos ML
J Neurosci; 2010 Oct; 30(40):13537-48. PubMed ID: 20926679
[TBL] [Abstract][Full Text] [Related]
5. Down syndrome cell adhesion molecule is conserved in mouse and highly expressed in the adult mouse brain.
Barlow GM; Micales B; Lyons GE; Korenberg JR
Cytogenet Cell Genet; 2001; 94(3-4):155-62. PubMed ID: 11856873
[TBL] [Abstract][Full Text] [Related]
6. Cystathionine beta-synthase is enriched in the brains of Down's patients.
Ichinohe A; Kanaumi T; Takashima S; Enokido Y; Nagai Y; Kimura H
Biochem Biophys Res Commun; 2005 Dec; 338(3):1547-50. PubMed ID: 16274669
[TBL] [Abstract][Full Text] [Related]
7. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.
Stoltzner SE; Grenfell TJ; Mori C; Wisniewski KE; Wisniewski TM; Selkoe DJ; Lemere CA
Am J Pathol; 2000 Feb; 156(2):489-99. PubMed ID: 10666378
[TBL] [Abstract][Full Text] [Related]
8. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.
Snow AD; Mar H; Nochlin D; Sekiguchi RT; Kimata K; Koike Y; Wight TN
Am J Pathol; 1990 Nov; 137(5):1253-70. PubMed ID: 2146882
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 5 in Down's syndrome hippocampus during development: increased expression in astrocytes.
Iyer AM; van Scheppingen J; Milenkovic I; Anink JJ; Lim D; Genazzani AA; Adle-Biassette H; Kovacs GG; Aronica E
Curr Alzheimer Res; 2014; 11(7):694-705. PubMed ID: 25115540
[TBL] [Abstract][Full Text] [Related]
10. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis.
Griffin WS; Sheng JG; McKenzie JE; Royston MC; Gentleman SM; Brumback RA; Cork LC; Del Bigio MR; Roberts GW; Mrak RE
Neurobiol Aging; 1998; 19(5):401-5. PubMed ID: 9880042
[TBL] [Abstract][Full Text] [Related]
11. The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains.
Oka A; Takashima S
Acta Neuropathol; 1999 Mar; 97(3):275-8. PubMed ID: 10090675
[TBL] [Abstract][Full Text] [Related]
12. Developmental immunohistochemistry of membrane proteins in the brain coded by a gene on human chromosome 21.
Takashima S; Kuruta H; Mito T; Konomi H; Obata R; Onodera K
Brain Res Dev Brain Res; 1990 May; 53(2):295-8. PubMed ID: 2141555
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-immunoreactive dystrophic neurites in Down's syndrome brains.
Mattiace LA; Kress Y; Davies P; Ksiezak-Reding H; Yen SH; Dickson DW
J Neuropathol Exp Neurol; 1991 Sep; 50(5):547-59. PubMed ID: 1654399
[TBL] [Abstract][Full Text] [Related]
14. ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons.
Helguera P; Pelsman A; Pigino G; Wolvetang E; Head E; Busciglio J
J Neurosci; 2005 Mar; 25(9):2295-303. PubMed ID: 15745955
[TBL] [Abstract][Full Text] [Related]
15. Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains.
Arai Y; Suzuki A; Mizuguchi M; Takashima S
Brain Dev; 1997 Jun; 19(4):290-4. PubMed ID: 9187481
[TBL] [Abstract][Full Text] [Related]
16. On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome.
Ohara S; Tsukada M; Ikeda S
Acta Neuropathol; 1999 Jan; 97(1):85-90. PubMed ID: 9930899
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed Down Syndrome Cell Adhesion Molecule (DSCAM) Deregulates P21-Activated Kinase (PAK) Activity in an In Vitro Neuronal Model of Down Syndrome: Consequences on Cell Process Formation and Extension.
Pérez-Núñez R; Barraza N; Gonzalez-Jamett A; Cárdenas AM; Barnier JV; Caviedes P
Neurotox Res; 2016 Jul; 30(1):76-87. PubMed ID: 26966010
[TBL] [Abstract][Full Text] [Related]
18. Nerve growth factor metabolic dysfunction in Down's syndrome brains.
Iulita MF; Do Carmo S; Ower AK; Fortress AM; Flores Aguilar L; Hanna M; Wisniewski T; Granholm AC; Buhusi M; Busciglio J; Cuello AC
Brain; 2014 Mar; 137(Pt 3):860-72. PubMed ID: 24519975
[TBL] [Abstract][Full Text] [Related]
19. Neuronal cell death in Down's syndrome.
Sawa A
J Neural Transm Suppl; 1999; 57():87-97. PubMed ID: 10666670
[TBL] [Abstract][Full Text] [Related]
20. Alteration of gene expression in Down's syndrome (DS) brains: its significance in neurodegeneration.
Sawa A
J Neural Transm Suppl; 2001; (61):361-71. PubMed ID: 11771759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
